Navigation Links
BioMarin Announces Third Quarter 2010 Financial Results
Date:10/28/2010

>BMN-701 for Pompe Disease: BioMarin expects to initiate a Phase I/II trial in Pompe patients in December 2010 or January 2011.  The company believes that BMN-701, a novel fusion of  insulin-like growth factor 2 and alpha glucosidase (IGF2-GAA) has the potential to be more efficacious and with a more favorable safety profile as compared to the currently approved product.
  • BMN-111 for Achondroplasia: BioMarin expects to file an IND by the end of 2011 and initiate a Phase 1 trial by the first quarter of 2012.  BMN-111 is an analog of C-type Natriuretic Peptide (CNP) for achondroplasia, a small cyclic peptide that is a positive regulator of bone growth.  Achondroplasia is the most common form of dwarfism.  There are approximately between 18,000 and 24,000 patients in the U.S. and Europe, 25 percent of which is the estimated addressable market.
  • Other early stage programs: BioMarin is working on multiple early development opportunities.

  • Non-GAAP Financial Information and ReconciliationThe above results for the three and nine months ended September 30, 2010 and September 30, 2009 and financial guidance for the year ending December 31, 2010 are presented both as determined in accordance with GAAP and on a non-GAAP basis.  As used in this release, non-GAAP income is calculated in accordance with GAAP, but excludes non-cash stock compensation expense, certain nonrecurring material items and the tax effect of the adjustments.  The following tables detail the reconciliation of non-GAAP to GAAP financial metrics:

    Reconciliation of GAAP Net Income (Loss) to Non-GAAP Net Income(In millions)(Unaudited)Three Months Ended September 30,Nine Months Ended September 30,Year Ended December 31,Year Ending December 31,Notes:2009201020092010 20092010(actuals)(forecast)GAAP Net Income (Loss)$

    6.6217.3$

    (5.2)$

    218.0$

    (0.5)$

    213.0 to 218.0Stock-based comp
    '/>"/>

    SOURCE BioMarin Pharmaceutical Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

    Related medicine technology :

    1. BioMarin to Host a Research and Development Day on October 19th
    2. BioMarin Appoints William Young and Kenneth Bate to Its Board of Directors
    3. BioMarin to Present at the UBS Global Life Sciences Conference
    4. BioMarin to Present at the Stifel Nicolaus Healthcare Conference
    5. BioMarin Receives Orphan Drug Designation from the FDA for BMN-701 for the Treatment of Pompe Disease
    6. BioMarin Acquires ZyStor Therapeutics, Inc.
    7. BioMarin Initiates Phase 3b Study to Evaluate the Effects of Kuvan on Neurophychiatric Symptoms in Subjects with PKU
    8. BioMarin to Acquire LEAD Therapeutics
    9. BioMarin to Present at the Credit Suisse Healthcare Conference
    10. BioMarin Announces Third Quarter 2009 Financial Results
    11. BioMarin to Present at the Oppenheimer Healthcare Conference
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/15/2014)... MultiCell Technologies, Inc. (OTC Bulletin Board: ... concerning composition of matter, biological targets, mechanism of action, ... This patent application describes a novel ... (VSRNAs) which interfere with the basic homeostatic cellular processes ...
    (Date:1/15/2014)...  According to Millennium Research Group (MRG), the global ... the United States and European transcatheter ... moderately through 2022, with embolization particles representing one ... in drug-eluting beads (DEBs) and radioembolization spheres in ...
    (Date:1/15/2014)... LAVAL, Quebec , Jan. 15, 2014  Valeant Pharmaceuticals ... VRX) announced that the applicable waiting period under the ... to the previously announced tender offer by its indirect ... the outstanding shares of common stock of Solta Medical, ...
    Breaking Medicine Technology:MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3
    ... , June 14 Upsher-Smith Laboratories, Inc. today ... for USL255 (extended-release topiramate), an internally developed program for the ... technology.  USL255 is designed to provide convenient once-daily dosing and ... topiramate options. , , ...
    ... /PRNewswire/ -- MedShape Solutions, Inc. was recently ... for their MORPHIX™ Suture Anchor at the recent Medical ... of jurors awarded the MORPHIX™ Anchor the Gold Award ... proprietary shape memory polymer, PEEK Altera™.  Previous winners of ...
    Cached Medicine Technology:Upsher-Smith Laboratories Announces Initiation of Phase III Clinical Trial of USL255 (Extended-Release Topiramate) for Adjunctive Treatment of Partial-Onset Epilepsy 2Upsher-Smith Laboratories Announces Initiation of Phase III Clinical Trial of USL255 (Extended-Release Topiramate) for Adjunctive Treatment of Partial-Onset Epilepsy 3MedShape Solutions, Inc. Receives Industry Honors and Awards 2
    (Date:7/10/2014)... omega 3 fatty acids had healthier joints than those ... fatty acids, according to Duke Medicine researchers. , The ... Diseases (10.1136/annrheumdis-2014-205601) on July 11, 2014, suggest that ... contribute to worsening osteoarthritis. , "Our results suggest that ... factors in the link between obesity and osteoarthritis," said ...
    (Date:7/10/2014)... July 10, 2014 One week ahead ... Worker Safety announced today it will extend compensation benefits ... months’ wages for workers displaced as a result of ... Alliance inspections have resulted in the closure of five ... five cases, raising immediate safety concerns. In May, the ...
    (Date:7/10/2014)... 2014 Best Drug Rehabilitation ... having family close by during a stay in ... or not the process is successful, has launched ... at http://www.bestdrugrehabilitation.com/success-stories/ . , The new Success ... from several Best Drug Rehabilitation graduates who wanted ...
    (Date:7/10/2014)... As the use of electronic health record becomes widespread ... implementation of the Affordable Care Act, the quantity of ... analytic purposes will also dramatically increase. Additionally, experts ... that analyze large quantities of data for the purpose ... the value of patient care a process that ...
    (Date:7/10/2014)... HealthDay Reporter THURSDAY, July 10, ... hot flashes that often accompany menopause, new research suggests. ... of menopausal women, said Dr. Taraneh Shirazian, an assistant professor ... School of Medicine at Mount Sinai Hospital in New York ... hot flashes a day, and she added that hot flashes ...
    Breaking Medicine News(10 mins):Health News:Omega 3 fatty acids lessen severity of osteoarthritis in mice 2Health News:Alliance for Bangladesh Worker Safety to Double Compensation for Displaced Factory Workers; Members Vote to Extend Wage Benefits from Two to up to Four Months 2Health News:Best Drug Rehabilitation Launches New Success Stories Section of Website 2Health News:Six cases where big data can reduce healthcare costs 2Health News:Six cases where big data can reduce healthcare costs 3Health News:Six cases where big data can reduce healthcare costs 4Health News:Losing Weight May Ease Hot Flashes, Study Finds 2Health News:Losing Weight May Ease Hot Flashes, Study Finds 3
    ... Coaches, trainers focus on prevention, better treatment for ... -- "Getting your bell rung." "A dinger." "Knocking ... a serious problem -- a concussion. , But ... are getting a lot better at spotting a ...
    ... barometer - gas prices go up, major ... market trend to stay home, shop online, REDMOND, Wash., ... offering over 30,000 supplements at,savings up to 50% today announced that ... quarters of 2008 as people change shopping habits to,offset today,s high ...
    ... Holmes,(Amex: HH ) today announced the sale ... Claims Evaluation Division (CED), a unit providing,independent medical ... for use in evaluating claims., The sale ... purchase,price of approximately $5.6 million. In one transaction, ...
    ... prices, biofuels, and climate change places 1.7,billion people ... risk of hunger, warns,anti-poverty agency ActionAid., WASHINGTON, ... in Hokkaido, Japan, ActionAid launches a new report, ... Global Food Crisis and What,They Can Do to ...
    ... NavigatorMD, Inc., a leading,benefits intelligence, software ... of Value-Based Plan Design development, announced,the addition ... Development and,Sales., Norris brings 24 years ... including market development and management. As Director ...
    ... - Thyroid cancer that has spread to distant sites has ... blood vessel formation can slow disease progression in some patients, ... Texas M. D. Anderson Cancer Center reports in the July ... . , The investigational drug, motesanib diphosphate, is a VEGF ...
    Cached Medicine News:Health News:Playing It Safe With High School Sports 2Health News:Playing It Safe With High School Sports 3Health News:Playing It Safe With High School Sports 4Health News:Photo: VitaminLife.com Sees Internet Sales Up 40% in Major Metro Markets as Gas Crisis Looms; Shopping Behaviors Change as People Conserve Gas 2Health News:Hooper Holmes Announces Sale of Claims Evaluation Division 2Health News:ActionAid Challenges G8 on Response to Food Crisis 2Health News:Marshall Norris Joins NavigatorMD as Director of Business Development and Sales 2Health News:Blood vessel inhibitor shows promise against metastatic thyroid cancer 2Health News:Blood vessel inhibitor shows promise against metastatic thyroid cancer 3Health News:Blood vessel inhibitor shows promise against metastatic thyroid cancer 4
    ... Stryker Threaded Dilator System ... another choice for drilling ... provide compaction reaming versus ... of bone within the ...
    ... The USS Sports Medicine Knot Pusher is a ... arthroscopic surgery. The Knot Pusher is utilized in ... and retrieving. The two piece shaft allows the ... slot for knot pushing. The ring handle allows ...
    ... Arthroscopy Scissor is ideal for excising soft tissue ... in the joint. The serrated edge on the ... as hold tissue within the jaws for more ... right jaw curvatures, are the perfect tools for ...
    ... Series I Instrument program offers state-of-the-art quality ... while maintaining strength and durability. Low profile ... tight joint spaces. Series I instruments are ... style, size and angle required for large ...
    Medicine Products: